Drugs / 3,3'-Dioxo-2,2'-bisindolylidene-5,5'-disulfonate disodium
3,3'-Dioxo-2,2'-bisindolylidene-5,5'-disulfonate disodium
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04228445 | Feb 2020 → Jun 2021 | ureteral disorder | Prove pharm | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 3,3'-Dioxo-2,2'-bisindolylidene-5,5'-disulfonate disodium | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04228445 ↗ |
| Modality | Diagnostic / imaging agent | “Experimental contrast dye that is commonly used as a visualization aid in pelvic and abdominal surgeries and for various diagnostic procedures in medical practice.” NCT04228445 ↗ |